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The objective of this study was to examine the potential of enhancing the antileukemic activity of arsenic trioxide (ATO) by
combining it with a folk remedy, crude methanolic extract of Mucuna macrocarpa (CMEMM). Human leukemia cells HL-60,
Jurkat, and Molt-3were treated with various doses ofATO, CMEMM, andcombinationsthereof for 24 and 48h. Results indicated
that the combination of 2.5μMA T Oa n d5 0μg/mL CMEMM synergistically inhibited cell proliferation in HL-60 and Jurkat cell
lines. Apoptosis triggered by ATO/CMEMM treatment was conﬁrmed by accumulation of cells in the sub-G1 phase in cell cycle
analyses, characteristic apoptotic nuclear fragmentation, and increased percentage of annexin V-positive apoptotic cells. Such
combinationtreatmentsalsoledtoelevationofreactiveoxygenspecies(ROS).TheantioxidantsN-acetyl cysteine(NAC),butylated
hydroxytoluene,andα-tocopherolpreventedcellsfromATO/CMEMM-inducedapoptosis.TheATO/CMEMM-inducedactivation
of caspase-3 and caspase-9 can be blocked by NAC. In summary, these results suggest that ATO/CMEMM combinationtreatment
exerts synergistic apoptosis-inducing eﬀects in human leukemic cells through a ROS-dependent mechanism and may provide a
promising antileukemic approach in the future.
1.Introduction
Arsenic is one of the oldest drugs in both Western and tradi-
tional Chinese (TCM)medicines. More than 2,000 years ago,
i tw a sﬁ r s tu s e dt ot r e a tv a r i o u sd i s e a s e sf r o ms y p h i l i st o
cancer [1]. Because it is both a therapeutic agent and a poi-
son, arsenic was used only to treat severe diseases with the
principle of “taming an evil with a toxic agent” in TCM [2].
In recent years, the clinical eﬃcacy of arsenic trioxide (ATO)
has been well characterized in the treatment of newly
diagnosed and relapsed acute promyelocytic leukemia (APL)
[3]. The combination of ATO and all-trans retinoic acid is a
veryeﬀectivenewstrategyforAPLpatientswhoareunableto
tolerateconventionaltherapy[4].Inaddition,invitrostudies
showed that ATO apparently aﬀected numerous intracellular
signal transduction pathways to alter cellular functions.
Therapeutic beneﬁts of ATO treatment involve antiprolif-
eration, antiangiogenesis, promotion of diﬀerentiation, and
induction of apoptosis in a wide variety of malignancies,
including both hematologic cancer and solid tumors [5, 6].2 Evidence-Based Complementary and Alternative Medicine
However,clinicaltrialsindicatethatATOasasingleagenthas
not demonstrated signiﬁcant beneﬁt in a variety of non-APL
hematological malignancies [7–9].
Mucuna macrocarpa Wallich (Leguminosae) is a large
woody climber distributed throughout Taiwan and South-
eastern Asia. In folk medicine, dried stems of this plant have
been used to fortify blood circulation for various hemato-
logic and circulatory related ailments [10]. A previous study
has reported that crude methanolic extract of M. macrocarpa
(CMEMM)exerts antileukemiceﬀectsby inductionofapop-
tosis in HL-60 human leukemia cells in vitro and in vivo,
providing thus scientiﬁc support of its putative clinical
eﬃcacy [11]. In addition, our preliminary study showed that
the CMEMM-induced apoptosis in human leukemia cells
might result from elevation of intracellular reactive oxygen
species (ROS). Since generation of a moderate prooxidant
environment may oﬀer potential therapeutic opportunities
in human leukemiacells, itwill be a goodstrategy toenhance
ATO cytotoxicity by adding a prooxidant agent [12]. More-
over, recent reports have demonstrated that ATO combined
with natural components such as dietary isothiocyanates
or ﬂavonoids could improve the eﬃciency of ATO as an
antileukemic drug [13–15].
For these reasons, we investigated the capacity of
CMEMM to enhance ATO cytotoxicity in human leukemia
cells (HL-60, Jurkat, and Molt-3). In the present study,
antiproliferative activity was evaluated by the trypan blue
exclusion assay. Apoptosis induced by combination of ATO
and/or CMEMM was determined by typical apoptotic mor-
phologic changes, cell cycle analyses, and Western blotting.
Also, changes in ROS production and glutathione (GSH)
levels were assessed. Furthermore, the free radical scav-
enger N-acetyl cysteine (NAC), butylated hydroxytoluene
(BHT),α-tocopherol,andcaspaseinhibitorz-VAD-fmk were
employed to further deﬁne the apoptotic mechanisms of the
ATO/CMEMM treatment.
2.Materialsand Methods
2.1. Reagents. RPMI-1640 medium, fetal bovine serum
(FBS),gentamicin, trypan blue dye solution, and phosphate-
buﬀered saline (PBS; pH 7.4) were purchased from Gibco
(Grand Island, NY, USA). Arsenic trioxide, N-acetyl cys-
teine, BHT, α-tocopherol,dimethyl sulfoxide(DMSO),dihy-
droethidium (DHE), and 4 ,6-diamidino-2-phenylindole
(DAPI) were purchased from Sigma (St. Louis, MO, USA).
Methanol was purchased from Merck (Darmstadt, Ger-
many). Cycle TEST PLUS DNA Reagent Kit was purchased
from Becton Dickinson (San Jose, CA, USA). ANNEX100F
Kit (annexin V: FITC assay kit) was purchased from
AbD Serotec (Kidlington, UK). M-PER mammalian protein
extraction reagent was purchased from PIERCE (Rockford,
IL, USA). Protease inhibitors cocktail and z-VAD-fmk were
purchased from Calbiochem (Darmstadt, Germany). Mouse
monoclonal antibody against caspase-3 was purchased from
Imgenex(SanDiego,CA,USA).Rabbitpolyclonalantibodies
against caspase-9, β-actin, and poly-ADP ribose polymerase
(PARP) were purchased from Imgenex, Sigma and Cell
Signaling Technology (Danvers, MA, USA), respectively. En-
hanced chemiluminescent (ECL) detection reagent was pur-
chased from PerkinElmer (Waltham, MA, USA).
2.2. Plant Material. Mucuna macrocarpa Wallich (Legumi-
nosae)wascollectedinNantouCounty,Taiwan. Thematerial
was identiﬁed by Professor Yuan-Shiun Chang of the Grad-
uate Institute of Chinese Pharmaceutical Sciences, China
Medical University. Crude methanolic extract of the stems
of M. macrocarpa (CMEMM) was prepared by extraction
with methanol and standardized byhigh-performance liquid
chromatography (HPLC)ﬁngerprint asdescribed indetailin
the preceding works [11].
2.3. Cell Culture and Drug Treatment. Human leukemia cell
lines HL-60 (acute promyelocytic leukemia), Jurkat, and
Molt-3 (acute T-lymphoblastic leukemia) were obtained
from the American Type Culture Collection (ATCC, Rock-
ville, Md). Cells were cultured in RPMI-1640 medium con-
taining 10% FBS and 0.01mg/mL gentamicin and incubated
in a humidiﬁed atmosphere of 5% CO2 at 37◦C. ATO
and CMEMM were dissolved in 0.1N NaOH and DMSO,
respectively, and diluted in culture medium. The ﬁnal
concentrations of NaOH and DMSO were not more than
5 × 10−5 N and 0.1%, which did not aﬀect cell viability. Cells
w e r et r e a t e dw i t h0 ,2 . 5a n d5 μM of ATO in combination
with 0, 25, 50, and 75μg/mL of CMEMM for 24 and 48h
and then harvested for various analyses.
2.4. Cell Proliferation Assay. Cell growth was determined
by the trypan blue exclusion assay. Cells were collected at
scheduled times following CMEMM and/or ATO exposure.
After centrifugation, cells were resuspended in culturemedia
and stained with 0.4% trypan blue solution. Viable cells
were countedusinga hemocytometer.Thepercentagesofcell
growth were calculated by comparing the cells number with
that of the control.
2.5. Cell Cycle Analysis. DNA staining was carried out using
Cycle TEST PLUS DNA Reagent Kit. In brief, cells (1 ×
106 cells/mL) were washed and stained for DNA content
according to the kit protocol. Fluorescence intensity of pro-
pidium iodide (PI) was determined using a FACScan ﬂow
cytometer and analyzed by ModFit LT software (Verity
Software House, Topsham, ME, USA).
2.6. Cytological Examination. DAPI nucleic acid stain was
used to observe apoptotic morphology of individual cells.
Brieﬂy, cells (1 × 106 cells/mL) were washed once with PBS,
collected on microscope slides by cytospin (Shandon Cy-
tospin Cytocentrifuge), ﬁxed with 10% neutral buﬀered
formalin, and stained with 2.5μg/mL DAPI solution at
room temperature. Photographs of the slides were taken
under an inverted ﬂuorescence microscopy (Olympus AX-
10). Fragmented nuclei were suggestive of apoptosis.
2.7.ROSProductionMeasurement. The probeDHEwas used
for detection of cytosolic superoxide anion (O2−). Brieﬂy,Evidence-Based Complementary and Alternative Medicine 3
Table 1: CI values for the combination of ATO and CMEMM in leukemia cell lines after 24h of treatment.
Drug combination Cell line
ATO CMEMM HL-60 Jurkat Molt-3
(μM) (μg/mL) CI Description CI Description CI Description
2.5 25 0.644 Synergism 1.043 Nearly additive 0.772 Moderate synergism
2.5 50 0.683 Synergism 0.802 Moderate synergism 0.935 Nearly additive
2.5 75 0.888 Slight synergism 0.820 Moderate synergism 1.155 Slight antagonism
5 25 0.887 Slight synergism 1.446 Moderate antagonism 0.852 Slight synergism
5 50 0.610 Synergism 0.868 Slight synergism 0.850 Moderate synergism
5 75 0.843 Moderate synergism 0.899 Slight synergism 1.021 Nearly additive
CI: combination index; ATO: arsenic trioxide; CMEMM: crude methanolic extract of Mucuna macrocarpa.
cells (1 × 106 cells/mL) were washed once with PBS and
stained with DHE-containing RPMI-1640 medium (without
phenol red) at a ﬁnal concentration of 10μM. After 30
minutes of incubation in a water bath at 37◦C, samples were
placed on ice for 10 minutes. Then, intracellular ROS levels
were immediately examined using a FACScanﬂow cytometer
and analyzed by CellQuest software (Becton Dickinson, San
Jose, CA, USA). Data are expressed as mean ﬂuorescence of
ethidium.
2.8. Annexin V-FITC/PI Analysis. Annexin V-FITC/PI stain-
ing method was used to identify and quantify apoptotic
cells. Cells (2 × 105) were treated according to the manufac-
turer’s instruction of ANNEX100F Kit. FITC/PI ﬂuorescence
intensity was measured by ﬂow cytometry to diﬀerentiate
between viable (annexin V-negative and PI-negative), early
apoptotic (annexin V-positive, PI-negative), and late apop-
totic(annexin V-positive and PI-positive) cells. The extent of
apoptosis was quantiﬁed as percentage of annexin V-positive
cells.
2.9.Western BlottingAnalysis. Toobtaintotalcellularprotein
extracts, cells (2 × 106) were washed once with PBS and
cell lysates were prepared by M-PER mammalian protein
extraction reagent supplemented with protease inhibitors
cocktail following the manufacturer’s protocol. Cell lysates
containing equal protein amounts were analyzed by Western
blotting as previously described [16]. In brief, samples
were subjected to electrophoretic separation in 12% SDS-
polyacrylamide gels, blotted onto nitrocellulose membranes,
and probed with primary antibodies against PARP, caspase-
3, caspase-9, and β-actin. Following wash cycles with TBS-
Tb u ﬀer (Tris-Buﬀer Saline with Tween 20), membranes
were incubated with horseradish peroxidase-conjugated sec-
ondary antibodies. Immunoreactive bands were visualized
using the ECL detection reagent and Kodak medical X-ray
processor.
2.10.DrugCombinationandStatistical Analysis. Toassess the
interaction of two drugs such as synergism, additivity, or
antagonism, the data ofcell proliferation assay were analyzed
by CalcuSyn V2 for Windows software (Biosoft, Cambridge,
UK). The combination indices (CIs) were calculated based
on the multiple drug eﬀect equation of Chou and Talalay,
where CI < 1, = 1, and >1 indicate synergism, additive
eﬀect, and antagonism, respectively [17, 18]. Each CI value
represents the mean of three independent experiments
which were performed in duplicates. Statistical signiﬁcant
diﬀerences between the control and ATO/CMEMM-treated
groups were estimated by one-way analysis of variance
(ANOVA)followed by Student-Newman-Keulstest using the
SPSS for Windows 10.0 version software. Diﬀerences were
deﬁned as signiﬁcant when P<0.05.
3.Results
3.1. ATO and CMEMM Synergistically Inhibit Cell Growth
on HL-60 Cells. To evaluate whether ATO and CMEMM
present additive, synergistic, or antagonistic eﬀect, HL-60,
Jurkat, and Molt-3 cells were treated with 2.5 or 5μM
ATO alone or in combination with increasing doses of
CMEMM from 25 to 75μg/mL. As shown in Figure 1,
CMEMM was found to enhance HL-60, Jurkat, and Molt-
3 cells to the growth inhibitory eﬀects of ATO for 24 or
48h treatment. CI values for the combination of ATO and
CMEMM after 24h of treatment were calculated and shown
in Table 1. Combination treatment of ATO and CMEMM
synergistically inhibited cell growth in HL-60 cells. However,
when combining 2.5μMA T Ow i t h7 5 μg/mL CMEMM or
5μMA T Ow i t h2 5 μg/mL CMEMM, the drug interaction
showed antagonism in Jurkat or Molt-3 cells, respectively.
3.2. ATO/CMEMM Combination Triggers Apoptosis in Leu-
kemic Cells. Since combination treatment of ATO and
CMEMM resulted in reduced cell growth, cell cycles of HL-
60 and Jurkat cells were analyzed using ﬂow cytometry. As
shown in Figure 2, treatments with ATOalone had negligible
or very low apoptosis in leukemic cells, as measured by the
accumulation of cells in the sub-G1 phase (or hypodiploid
apoptotic cells). However, cotreatment of 2.5μMA T Oa n d
50μg/mL CMEMM for 24h increased cells in the sub-G1
phase. As treatments prolonged up to 48h, the accumulation
of cells in the sub-G1 phase increased more obviously in
Jurkat cells (Figure 2(b)) than in HL-60 cells (Figure 2(a)).
Additionally, as shown in Figure 3 of nuclear morphological
changes in 2.5μMA T O -a n d / o r5 0μg/mL CMEMM-treated
cells, ATO/CMEMM-treatedcellspresentedwith fragmented
chromatin and formation of apoptotic bodies, which were in4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Antiproliferative eﬀects of combined application of arsenic trioxide (ATO) and crude methanolic extract of Mucuna macrocarpa
(CMEMM) on human leukemia cells. HL-60, Jurkat, or Molt-3 cells (1 × 105 cells/mL) were seeded into 6-well plates and exposed to 0, 2.5,
or 5μM ATO alone or together with 0, 25, 50, or 75μg/mL CMEMM for 24 and 48h. Vehicle control cells were treated with 0.1% DMSO
in medium. The percentages of cell growth were measured by the trypan blue exclusion assayand calculated by comparing the cells number
withthat ofthevehiclecontrols.Each valuerepresents themean ± S.E.of duplicate cultures fromthree independent experiments. ∗P<0.05,
∗∗P<0.01 indicate signiﬁcant diﬀerence from the respective control value.
clear contrast with the intact nuclei of control groups. The
apoptotic morphology results together with the ﬂow cytom-
etry data suggest that cotreatment exerted higher apoptosis-
inducing eﬀect than treatment of ATO or CMEMM alone.
3.3. ATO/CMEMM Combination Induces Apoptosis in Leuke-
mic Cells through a ROS-Dependent Mechanism. Since ATO
or other DNA damaging agents may trigger oﬀ the apoptotic
pathway through the production of ROS, we sought to
assess the role of ROS generation in ATO/CMEMM-induced
apoptosis using the oxidant sensitive probe DHE. As shown
in Figure 4, intracellular ROS content of ATO/CMEMM-
treated HL-60and Jurkat cellsincreased in a time-dependant
manner within 16 to 48h and 4 to 48h periods, respectively.Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: Cell cycle progression in leukemiacells exposed to arsenictrioxide (ATO) and/orcrude methanolic extract of Mucuna macrocarpa
(CMEMM). HL-60 (a) or Jurkat (b) cells (1 × 105 cells/mL) were ﬁrst treated with 5mM N-acetyl cysteine (NAC) or untreated, followed by
treatment with 0.1% DMSO (CTL), 2.5μMA T O ,a n d / o r5 0μg/mL CMEMM as indicated. After 24 or 48h of treatment, cells were collected
and stained with propidium iodide and determined for DNA content using ﬂow cytometry. The percentages of sub-G1 or hypodiploid cells
were analyzed by ModFit LT software. The representative cell cycle progressions in ATO- and/or CMEMM-treated or control cells were from
one of three independent experiments.Evidence-Based Complementary and Alternative Medicine 7
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Figure 3: Nuclear morphological changes induced by arsenic trioxide (ATO) and/or crude methanolic extract of Mucuna macrocarpa
(CMEMM). HL-60, Jurkat, or Molt-3 cells (1 × 105 cells/mL) were treated with 0.1% DMSO (control), 2.5μMA T O ,5 0μg/mL CMEMM,
or 2.5μMA T Op l u s5 0μg/mL CMEMM. After 24 or 48h of incubation, cells were washed with PBS and collected on microscope slides by
cytospin. The nuclei were stained with 2.5μg/mL DAPI. Arrows indicate apoptotic bodies of nuclear fragmentation.Magniﬁcation × 200.
To further demonstrate that the apoptosis triggered by ATO-
CMEMM treatment is mediated by higher production of
ROS, the eﬀect of the free radical scavenger NAC was
evaluated. The possibility of direct interaction between ATO
and NAC was already excluded in a previous report [19].
As shown in Figure 2, addition of 5mM NAC treatment
decreased the accumulation of cells in sub-G1 phase as
compared to those observed in ATO/CMEMM-treated cells.
Furthermore, the annexin V-FITC/PI assay was employed
to investigate whether other antioxidant agents could also
attenuate the apoptosis induced by cotreatment of ATO and
CMEMM in HL-60 and Jurkat cells. As shown in Figure 5,
the percentage of apoptotic cells (annexin V-positive) in-
creased from 2.18% (ATO only) or 3.65% (CMEMM only)
to 25.36% (ATO + CMEMM) in ATO/CMEMM-treated HL-
60 cells after 24h of exposure. Using the same treatment,
the percentage of apoptotic cells increased from 6.86%
(ATO only) or 3.89% (CMEMM only) to 23.81% (ATO +
CMEMM) in ATO/CMEMM-treated Jurkat cells. The syner-
gistic apoptosis-inducing eﬀects were signiﬁcantly decreased
notonlybyNAC(2.51%or7.70%ofapoptoticcells)butalso
byBHT(12.79%ofapoptoticcells)andα-tocopherol(8.55%
of apoptotic cells) in HL-60 and Jurkat cells, respectively.
These results together suggest that the ATO/CMEMM-
induced apoptosis in leukemia cells was mediated by oxida-
tive stress.
3.4. ATO/CMEMM Combination Induces Apoptosis via the
Intrinsic Pathway. Inductionofapoptosisthroughtheintrin-
sic, mitochondrial pathway was further investigated in
leukemia cells via assessment of cleavage/activation of cas-
pase-3, caspase-9, and PARP. As shown in Figure 6,h i g h e r
levelsofcleavedcaspase-3, caspase-9, and PARPwere present
in HL-60 and Jurkat cells exposed to the combination of
ATO/CMEMM than with ATO alone. Additionally, addition
of NAC in the combination treatment signiﬁcantly inhibited
the action of cleavage in these apoptosis-regulatory factors.
4.Discussionand Conclusions
Since ATO has had remarkable success in the treatment of
APL, an increasing number of preclinical studies to broaden
the therapeutic potential have been reported during the last
decade. Unfortunately, ATO as a single agent has demon-
stratedonlylimitedbeneﬁtinnon-APLhematologicalmalig-
nancies. Recently, combinatorial treatment has been con-
sidered a good strategy to enhance ATO cytotoxicity by
combining itwith a prooxidant agentor natural components
in vitro. In the present study, the results revealed that
antileukemic activity of ATO was potentiated by combining
it with a folk remedy, CMEMM through enhancing growth
inhibition(Figure 1)andincreasing theinductionofapopto-
sis via a ROS-dependent mechanism (Figures 2, 3, 4,a n d5)
and intrinsic, mitochondria-mediated pathway (Figure 6).
Accordingly, ﬁndings from the present study provide sci-
entiﬁc support as well as the elucidation of the underlying
mechanisms of synergistic antileukemic activities mediated
by ATO and CMEMM.
Drug interaction of ATO and CMEMM was evaluated
by CI values (Table 1). Interestingly, ATO and CMEMM
synergistically inhibit cell growth on HL-60 cells, whereas
variable eﬀects were exerted by combining ATO with dif-
ferent doses of CMEMM on Jurkat and Molt-3 cells. As
combined 2.5μMA T Ow i t h 7 5 μg/mL CMEMM or 5μM
ATO with 25 μg/mLCMEMM,thedruginteractionindicated
antagonism in Jurkat or Molt-3 cells, respectively. The
discrepancy in drug interaction between promyelocytic and
lymphoid leukemia cells could be attributed to diﬀerences
in cell-type speciﬁc molecular or genetic factors [20]. For
instance, the degradation of PML-RARalpha protein, an
APL marker protein resulting from chromosomal t(15; 17)
translocation, or the reduction of genomic methylation
level may be involved in drug interactions of antileukemic
agents in diﬀerent leukemia cells [21–23]. For future ther-
apeutic application, the determination of optimum dose of8 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Changes in the level of intracellular reactive oxygen species (ROS) in leukemia cells exposed to arsenic trioxide (ATO) and/or
crude methanolicextract of Mucuna macrocarpa (CMEMM).HL-60 (a) or Jurkat (b) cells (1 × 105 cells/mL) were treated with 0.1%DMSO
(control), 2.5μMA T O ,5 0 μg/mL CMEMM, or 2.5μMA T Op l u s5 0μg/mL CMEMM for 4 to 48h. Then, cells were washed with PBS,
incubated with dihydroethidium for 30min,and analyzed for red ﬂuorescence by ﬂow cytometry. The mean ﬂuorescence intensity was used
as read-out for intracellular ROS levels.10 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Annexin V-FITC/propidium iodide (PI) analyses of arsenic trioxide (ATO)- and/or crude methanolic extract of Mucuna macro-
carpa(CMEMM)-treated cells.HL-60(a)andJurkat(b)cells (1×105 cells/mL)wereﬁrsttreated with5mMN-acetyl cysteine(NAC),50μM
butylated hydroxytoluene (BHT), or 40μM α-tocopherol (VitE) or untreated, followed by treatment with 0.1% DMSO (CTL), 2.5μMA T O ,
and/or 50μg/mL CMEMM as indicated for 24h. Quantitative percentages of apoptotic cells of ATO/CMEMM-treated cells were measured
by ﬂow cytometry. Data represent the result from one of three independent experiments.Evidence-Based Complementary and Alternative Medicine 11
−
−
−
+
++
++
+
+
−
−
+
−
−
−−−
−
− ATO (2.5μM)
CMEMM (50μg/mL)
NAC (5mM)
Pro-caspase-3 (32kDa)
Cleaved-caspase-3 (14–21kDa)
Pro-caspase-9 (50kDa)
Cleaved-PARP (89kDa)
β-actin (43kDa)
Pro-caspase-3 (32kDa)
Cleaved-caspase-3 (14–21kDa)
Pro-caspase-9 (50kDa)
Cleaved (35kDa)
Cleaved-PARP (89kDa)
β-actin (43kDa)
HL-60
Jurkat -caspase-9
Cleaved (35kDa) -caspase-9
Figure 6: Expressions of apoptosis-related proteins in leukemia cells treated with arsenic trioxide (ATO), crude methanolic extract of
Mucuna macrocarpa (CMEMM), and/or N-acetyl cysteine (NAC). Whole cell lysates were prepared from HL-60 or Jurkat cells treated with
2.5μMA T O ,5 0μg/mL CMEMM, 5mM NAC, or indicated combinations for 24h. Proteins as indicated were analyzed by Western blotting
with β-actin as loading control. Representative blots shown were from one of three independent experiments.
ATO/CMEMM-combined treatment will be a worthwhile
task. Furthermore, the synergism or antagonism determi-
nation is entirely based on the mass-action law princi-
ple of the median-eﬀect equation. Since the synergism
is not observed in general when apoptosis is studied in
Figure 2 and Figure 6,i ts h o u l db en o t e dt h a ts y n e r g i s m
or antagonism determination is mechanism independent,
drug unit independent, and dynamic order independent
[18]. Nevertheless, the results of annexin V-FITC/PI analyses
showed that the synergistic eﬀects of apoptosis were induced
by combining ATO at a clinically achievable concentration
(2.5μM) with 50μg/mL CMEMM in HL-60 and Jurkat cells
(Figure 5).
ROS, such as superoxide anion and hydrogen peroxide,
are toxic byproducts of cellular metabolism. Although ROS
at moderate concentration are not toxic but rather act as sig-
naling molecules, theiroverproductionand/oraccumulation
can cause nonspeciﬁc damage to proteins, nuclear acids, and
other cellular components [24, 25]. ATO-stimulated ROS
generationinculturedcellsiswellrecognized.Invitrostudies
haveindicatedthatthepathwayresponsibleforATO-induced
apoptosis on leukemic cells is through NADPHoxidase [26],
mitochondrial electron transport chain [27], or the inhibi-
tion of antioxidant enzymes such as thioredoxin reductase
(TrxR) [28] and glutathione peroxidase (GPx) [29], thereby
inducing ROS-dependent apoptosis. For these reasons, in
the current study we demonstrated the important role of
ROS generation in the ATO/CMEMM-mediated apoptosis
(Figures 4 and 5). Similarly, recent studies reported that
ATO-provoked apoptosis could be augmented by natural
polyphenols, such as quercetin, genistein, and curcumin, in
human leukemia cells through the generation of a prooxi-
dant environment [14, 15, 30]. Taken together, prooxidant
environment can be induced by polyphenols in combination
with ATO to result in the potentiation of antileukemic eﬀect
via overproduction of ROS.
To discern whether ROS overproduction is a late con-
sequence of damage (e.g., mitochondrial damage) in ATO/
CMEMM-treated leukemia cells, the cell proliferation assay
and superoxide production measurement were also per-
formed at an earlier stage. Our preliminary results showed
that no signiﬁcant growth inhibition was observed in12 Evidence-Based Complementary and Alternative Medicine
ATO/CMEMM-treated Jurkat and HL-60 cells after 16h
of exposure (data not shown). In the meanwhile, the super-
oxide productions of ATO/CMEMM-treated Jurkat cells
increased in a time-dependant manner within 4 to 16h
period while that of ATO/CMEMM-treated HL-60 cells
slightly increased at 16h (Figure 4). Therefore, before the
cytotoxicity was evident the increase of ROS accumulation
in Jurkat cells was more obviously than HL-60 cells. Fur-
thermore, we also performed mitochondrial superoxide pro-
duction measurement in ATO/CMEMM-treated leukemia
cells. The results showed that mitochondrial superoxide
production signiﬁcantly increased in ATO/CMEMM-treated
JurkatandHL-60cellsafter24hofexposure,andtheincreas-
ing pattern was similar to that of intracellular superoxide
production (data not shown). As we know, oxidative stress
elicited by overproduction of ROS in mitochondria may
triggerapoptosisbyinhibitionoftheubiquitinationandpro-
teasomal degradation system or activation of protein kinase
C-δ [31]. These preliminary results implied that oxidative
stress induced by mitochondrial superoxide production may
play an important role in ATO/CMEMM-induced apoptosis.
Moreover, changes in the intracellular milieu of the cells,
such as alterations in the redox environment, have been
indicatedasimportant regulatorsoftheprogression toapop-
tosis [32]. Depletion of glutathione (GSH) or superoxide
dismutase (SOD) has been shown to play an important role
in cell survival and act as a target for the selective killing
of cancer cells [33, 34]. However, our preliminary results
showed that relative levels of total intracellular GSH or SOD
did not signiﬁcantly decrease in ATO/CMEMM-treated HL-
60 or Jurkat cells as compared to controls (data not shown).
Since the exact mechanisms involved in the regulation of
apoptosis by GSHor SODremain elusive, otherregulators of
apoptosissuch asglutathionylation (protein-SSG)and nitro-
sylation (protein-SNO) may be involved in redox-directed
cytotoxicity [35]. Therefore, further investigation may focus
on the role of oxidative protein modiﬁcations in the redox
environment generated by combinatorial treatment of ATO
and CMEMM.
To determine whether ATO/CMEMM combination in-
duces caspase-dependent cell death, we further evaluated
ATO/CMEMM-induced apoptosis in the presence of a pan-
caspase inhibitor, z-VAD-fmk by ﬂow cytometry. After 24h
of combination treatment of 2.5μMA T Oa n d5 0 μg/mL
CMEMM, the frequency of apoptosis was greatly reduced
by the addition of 25μM z-VAD-fmk in Jurkat cells but not
in HL-60 cells (data not shown). It is noteworthy that the
percentages of necrotic cells, annexin V-positive, and PI-
positive, in ATO/CMEMM-treated HL-60 and Jurkat cells,
were13.17%and2.22%,respectively(Figure 5).Thisimplied
that z-VAD-fmk did not reduce apoptosis generation in HL-
60 cells which may result from the distinct mode of necrotic
death. Also, the possibility of other caspase-independent
modes of death may be considered.
Dried stems of M. macrocarpa are used as blood-acti-
vating and stasis-resolving herbs to relieve symptoms related
to leukemia in folk medicine [10]. Phytochemical compo-
nents of CMEMM were analyzed by chromatography and
spectroscopy in our previous study [11]. Several bioactive
isoﬂavones including calycosin, afrormosin, and genistein
were identiﬁed in CMEMM with pure markers standards
using HPLC. Calycosin and afrormosin have been reported
to exhibit growth inhibition in U937 lymphoma cells [36]
and inhibitory eﬀects on TPA-induced skin tumor promo-
tion in mouse [37], respectively. Moreover, genistein has
been found to be an antileukemic agent [38]a n da l s oa
prooxidant to potentiate ATO-provoked apoptosis in human
leukemia cells via reactive oxygen species generation [15].
The concentration of genistein to enhance ATO-provoked
apoptosis was at 50μM after 24h of exposure in HL-60,
THP-1, Jurkat, RPMI-8866, and U937 human leukemia
cells. Since our previous HPLC quantitative analysis showed
that the content of genistein was 0.001% in dried stems
of M. macrocarpa (data not shown), it was reasonable to
assume that the low content of genistein was not the main
component in CMEMM that enhanced ATO cytotoxicity in
HL-60 and Jurkat cells. This implied that the synergistic
antileukemic activity of cotreatment of ATO and CMEMM
mayhaveresultedfromtheinteractionofmultipleﬂavonoids
instead of a single eﬀective constituent such as genistein.
Furthermore, our previous mouse xenograft study showed
that no obvious acute toxicity of CMEMM at 500mg/kg/day
was observed during the treatment period [11]. The novel
ﬁnding is that ATO can be combined with clinical achiev-
able doses of CMEMM in inhibiting growth of leukemia
cells.
In conclusion, we presented evidence that treating hu-
man leukemia cells with CMEMM led to the potentiation
of ATO cytotoxicity via a ROS-dependent mechanism. The
synergistic drug interaction correlates with the prooxidant
action of CMEMM, as measured by ROS overproduction,
and the activation of apoptosis-regulatory proteins, caspase-
3 and caspase-9. Consequently, our results suggest that
combinatorial treatment of ATO and CMEMM may provide
a beneﬁcial therapeutic approach in the future.
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